{"analyses":[{"ciLowerLimit":"1.1","ciPctValue":"95","ciUpperLimit":"2.6","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":".03","paramType":"Hazard Ratio (HR)","paramValue":"1.65","statisticalComment":"Statistical analysis did not count treatment continuing beyond 2 years as efficacy failure (n = 2 in each arm).","statisticalMethod":"Regression, Cox","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"40"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"77"}],"units":"Participants"}],"description":"Administration of secondary systemic therapy for chronic GVHD, death during primary therapy, or onset of recurrent malignancy or bronchiolitis obliterans during primary therapy","groups":[{"description":"Patients receive oral mycophenolate mofetil 1000 mg twice daily.","id":"OG000","title":"Mycophenolate Mofetil"},{"description":"Patients receive oral placebo twice daily","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2 years","title":"Definitive Absence of Efficacy Success","type":"SECONDARY","unitOfMeasure":"participants"}